|
µî·ÏÀÏ:
2004-04-14 10:51:44 , Á¶È¸:
3,080 |
(ÀÓ»ó1) °Ç°ÇÑ ¼ºÀÎ ³²ÀÚ¿¡°Ô¼ÀÇ ´Üȸ ¹× ¹Ýº¹ Åõ¿© ½ÃÇè1)
´ë»ó: ¾ÆÅäÇÇÇǺο° ȯÀÚ°¡ ¾Æ´Ñ ÀϹÝÀÎ. 22-42¼¼. 14¸í
½ÃÇà¾à¹°: ÇÁ·ÎÅäÇÈ(Ÿũ·Î¸®¹«½º) 0.03%, 0.1%, 0.3%(ÀÓ»ó¿ë), ±âÁ¦
¹æ¹ý: 1ÀÏ 1ȸ 4ÀÏ°£ 1000cm2 µµÆ÷
°á°ú: Ç÷Áß¿¡¼ Ÿũ·Î¸®¹«½ºÀÇ ³óµµ°¡ ÃøÁ¤µÇÁö ¾ÊÀ½.
ÇÁ·ÎÅäÇÈÀº °Ç°ÇÑ ÇǺο¡¼´Â Èí¼ö°¡ µÇÁö ¾Ê½À´Ï´Ù.
ÇÁ·ÎÅäÇÈÀº ºÐÀÚ·®ÀÌ Å©°í ÇǺΠ¼±ÅÃÀû(skin selective)ÀÌ¾î¼ ¾ÆÅäÇÇÇǺο° º´º¯ÀÌ ÀÖ´Â °÷¿¡¼ Èí¼ö°¡ ÀÌ·ç¾îÁö¸ç,
ÇǺΰ¡ °³¼±ÀÌ µÇ¾î °Ç°ÇØÁö¸é Èí¼ö°¡ µÇÁö ¾Ê´Â ¹Ý¸é, ½ºÅ×·ÎÀ̵å´Â °Ç°ÇÑ ÇǺο¡µµ Èí¼ö°¡ µË´Ï´Ù.
(ÀÓ»ó2) Àå±â Àü½Å Èí¼ö °üÂû ½ÃÇè2)3)4)
´ë»ó: ¼ºÀÎ(631¸í) ¹× ¼Ò¾Æ(351¸í) ¾ÆÅäÇÇÇǺο° ȯÀÚ
½ÃÇà¾à¹°: Ÿũ·Î¸®¹«½º 0.1% ¹× 0.03%
¹æ¹ý: 1ÀÏ 2ȸ 12ÁÖ°£ µµÆ÷
°á°ú: ¼Ò¾Æ´Â 100%, ¼ºÀÎÀº 99.7%°¡ Ç÷Áß³óµµ 5ng/ml¹Ì¸¸
(ÀÓ»ó3) ¼Ò¾Æ Àü½Å Èí¼ö °üÂû ½ÃÇè5)
´ë»ó: 2-15¼¼ ¼Ò¾Æ ¾ÆÅäÇÇÇǺο° ȯÀÚ. 189¸í
½ÃÇà¾à¹°: Ÿũ·Î¸®¹«½º 0.03%
¹æ¹ý: 1ÀÏ 2ȸ 3ÁÖ°£ µµÆ÷
°á°ú: Àüü ȯÀÚÀÇ 98.4%°¡ Ç÷Áß³óµµ 1ng/ml ÀÌÇÏÀÓ.
°¡Àå ³ô°Ô ÃøÁ¤µÈ ·¹º§Àº 2.75ng/ml¿´À½.
Àü½ÅÈí¼ö¸¦ ³ªÅ¸³ª´Â ÃÖ¼Ò°ªÀº 5ng/mlÀ¸·Î ±× ¹Ì¸¸ÀÏ °æ¿ì ¸é¿ª¾ïÁ¦¸¦ ÇÏÁö ¾Ê´Â´Ù°í º¼ ¼ö ÀÖ½À´Ï´Ù.
°á·Ð: ÇÁ·ÎÅäÇÈÀº ¾ÆÅäÇÇÇǺο°ÀÇ º´º¯¿¡¸¸ ¼±ÅÃÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ÃÖ¼ÒÀÇ Àü½ÅÈí¼ö¸¦ ³ªÅ¸³»¾î, Àü½Å¸é¿ª¾ïÁ¦¸¦ ÇÏÁö ¾Ê½À´Ï´Ù.
¹ßÃé:
1) I. Berkersky et al, Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001; 44: S17-27
2) Jon M. Hanifin,MD. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part1, Efficacy, J Am Acad Dermatol,2001; 44: S28-38
3) Jon M. Hanifin,MD. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part2, Safety, J Am Acad Dermatol,2001; 44: S39-46
4) A 12 weeks study of tacrolimus ointment for the atopic dermatitis in pediatric patients. J Am Acad Dermatol,2001; 44: S47-57
5) T. Ruzicka, for the European/Canadian Tacrolimus ointment study group. Pediatric patients with moderate to severe atopic dermatitis treated with tacrolimus ointment 0.03% show minimal systemic exposure: poster from 20th WCD
|
|